



Check for updates

REVIEW

Recent advances in understanding HIV evolution [version 1; referees: 2 approved]

Sophie M. Andrews, Sarah Rowland-Jones 

Nuffield Department of Clinical Medicine, University of Oxford, NDMRB, Oxford, UK



v1 First published: 28 Apr 2017, 6(F1000 Faculty Rev):597 (doi: 10.12688/f1000research.10876.1)

Latest published: 28 Apr 2017, 6(F1000 Faculty Rev):597 (doi: 10.12688/f1000research.10876.1)

Abstract

The human immunodeficiency virus (HIV) evolves rapidly owing to the combined activity of error-prone reverse transcriptase, recombination, and short generation times, leading to extensive viral diversity both within and between hosts. This diversity is a major contributing factor in the failure of the immune system to eradicate the virus and has important implications for the development of suitable drugs and vaccines to combat infection. This review will discuss the recent technological advances that have shed light on HIV evolution and will summarise emerging concepts in this field.

Open Peer ReviewReferee Status:  

	Invited Referees	
	1	2
version 1 published 28 Apr 2017		

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty. In order to make these reviews as comprehensive and accessible as possible, peer review takes place before publication; the referees are listed below, but their reports are not formally published.

- 1 **Philippe Lemey**, Rega Institute, KU Leuven Belgium
- 2 **Ben Berkhout**, University of Amsterdam (UvA) Netherlands

Discuss this article

Comments (0)

Corresponding author: Sarah Rowland-Jones (sarah.rowland-jones@ndm.ox.ac.uk)

How to cite this article: Andrews SM and Rowland-Jones S. **Recent advances in understanding HIV evolution [version 1; referees: 2 approved]** *F1000Research* 2017, **6**(F1000 Faculty Rev):597 (doi: [10.12688/f1000research.10876.1](https://doi.org/10.12688/f1000research.10876.1))

Copyright: © 2017 Andrews SM and Rowland-Jones S. This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

Grant information: Sarah Rowland-Jones is supported by grants from the Rosetrees Foundation (A1138), Globvac (Norwegian Research Council), and the Centre for AIDS Research, Kumamoto University. Sophie M. Andrews is supported by the Rosetrees Trust (A1138). *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Competing interests: The authors confirm that they have no competing interests.

First published: 28 Apr 2017, **6**(F1000 Faculty Rev):597 (doi: [10.12688/f1000research.10876.1](https://doi.org/10.12688/f1000research.10876.1))

Introduction

The human immunodeficiency virus (HIV) is a major cause of morbidity and mortality worldwide, and infection leads to acquired immune deficiency syndrome (AIDS) and death in the overwhelming majority of untreated patients. Despite this, no effective vaccine or cure has yet been developed. A major obstacle in this endeavour is that rapid viral evolution essentially renders HIV a “moving target”, which also contributes to the inability of the host to control and clear the virus in natural infection. Understanding how HIV evolves is therefore of high priority, and substantial progress has been made in recent years. This review will discuss the latest technological advances that have shed light on HIV evolution and will summarise emerging concepts in the field.

Why does HIV evolve rapidly?

HIV evolves extremely rapidly, exhibiting the highest recorded biological mutation rate currently known to science. The inter-patient genome-wide nucleotide substitution rate of intracellular viral DNA may be as high as 4.1×10^{-3} ($2.4 \times 10^{-3} - 5.8 \times 10^{-3}$) substitutions per site per year (s/s/y) and, in the hypervariable regions of the envelope (*env*) gene, could reach 5.2×10^{-3} ($2.9 \times 10^{-3} - 7.7 \times 10^{-3}$) s/s/y².

The rapid rate of HIV evolution is largely attributable to the error-prone nature of reverse transcriptase, which plays an important role in viral replication yet lacks proofreading activity. This, in combination with short generation times, allows mutations to accumulate quickly within the virus at rates that differ across the genome³. As the duration of infection is prolonged—with clinical latency lasting around a decade in untreated individuals—and the replicating population is large, the degree of viral diversity within a patient can be extensive⁴.

In addition, one or more viruses may undergo recombination to produce a unique recombinant form (URF). Recombination can occur between highly divergent, closely related, or even identical viruses within a patient, and the evolutionary impact of the recombination event will be affected by the degree of divergence between the initial “parental” variants. If the resulting URF spreads amongst a population, it becomes a circulating recombinant form (CRF). Recombination of various simian immunodeficiency viruses (SIVs) is believed to have been an important contributing factor in the cross-species transmission and evolution of HIV from SIVs infecting non-human primates. It is also believed to have contributed substantially to the diversification of HIV-1 group M subtypes⁵.

Another potential source of variation is guanosine to adenosine (G-to-A) mutation induced by the host restriction factors APOBEC3G and APOBEC3F (A3G/F)^{6,7}, but the contribution of A3G/F to viral evolution is controversial. Analysis of whole viral genomes failed to detect evidence of A3G/F footprints⁸, and it has been proposed that the excessive degree of G-to-A hypermutation may be lethal, even in the context of very low levels of APOBEC3G⁹. However, later studies have suggested that whilst low-level G-to-A mutagenesis may contribute to viral evolution¹⁰, the overall contribution of this effect is likely to be small¹¹.

Mutations may accumulate either because of genetic drift or because they confer a relative fitness advantage to the virus, allowing it to persist and replicate more successfully than in its previous state. Escape mutations often confer a degree of resistance against selection pressure exerted by drugs or the host immune response, and evidence of viral evolution driven by cytotoxic lymphocytes (CTLs) and antibodies can even be detected in infants¹². HIV-1 is known to adapt to host HLA class I^{13,14}, and up to 56% of polymorphic sites in viral genes may be subject to HLA-associated selection pressure¹⁵.

Whilst many studies have been performed *in vitro*, HIV has also been shown to evolve rapidly *in vivo*¹. This has obvious biological implications as untreated patients eventually lose control over the virus and progress to AIDS. Whether or not HIV continues to replicate during antiretroviral therapy (ART) is currently subject to debate, with conflicting studies suggesting evidence both for¹⁶ and against persistent, on-going replication contributing to the maintenance of the viral reservoir during treatment¹⁷.

How does the virus evolve within and between hosts?

HIV infection is usually established from a single transmitted founder virus^{18–20}. How this one virus then diversifies within an individual has been the subject of numerous studies. Early longitudinal studies of envelope sequences within patients identified consistent evolutionary patterns associated with disease progression²¹ and CD4⁺ lymphocyte decline²². In the late stages of infection, sequence divergence tends to stabilise as a result of the reduced selection pressure that can be exerted by a severely damaged immune system²³. As the rate of disease progression varies between patients, attempts have also been made to identify whether evolutionary factors contribute to these differences. It is now known that synonymous rather than non-synonymous substitution rates are associated with disease progression, most likely owing to underlying replication dynamics, which may in turn be driven by excessive immune activation²⁴. Primary infection may also be established from two or more strains. Such co-infections are more frequently observed with injection drug use than sexual routes of transmission, and the viruses can undergo recombination, which significantly expands the genetic diversity of the quasispecies pool²⁵.

Whilst HIV evolves extremely rapidly within individuals, viral evolution is somewhat slower on a population level, reviewed by Lemey *et al.*². Most evolutionary studies have been performed using the *env* gene, but the rate of inter-host viral evolution is consistently lower across the whole viral genome³. Several hypotheses have been proposed to explain this anomaly, including fluctuations in selection pressure over time, reversion of patient-specific adaptive changes following transmission, and a “store and retrieve” mechanism in which archived ancestral virus is preferentially transmitted²⁶. The last proposal is currently the most well supported²⁷. Such cycles of latency are believed to occur irrespective of treatment, and the proportion of viruses in the plasma that have gone through latency is believed to be large²⁸. Cycling in and out of latency is therefore likely to make a non-trivial impact on viral evolution.

Another key question in HIV evolution concerns the establishment of primary infection and whether the virus responsible possesses favourable characteristics or is merely in the right place at the right time. Despite the diversification of virus within a patient, infection is typically established with CCR5 tropic (R5) virus containing specific residues associated with increased viral fitness²⁹. However, the selection bias imposed by this genetic bottleneck is significantly reduced in more permissive environments, such as in the context of inflammation, and the bottleneck itself is affected by the mode of sexual transmission³⁰. Viruses that are pre-adapted to the HLA types of the recipient are also associated with higher viral loads, rapid CD4⁺ lymphocyte decline, and a poorer prognosis³¹.

How has HIV evolved since its emergence?

HIV is an evolutionarily young virus, having first emerged in the first half of the 20th century^{32,33}. How the virus has disseminated and evolved since then is of great epidemiological interest, and advances in the field of phylogeography have helped to address these questions. Phylogeographic studies combine genetic and geographical data to draw inferences about historical events that have contributed to the current geographic distribution of a virus. The use of such an approach enabled the determination of the likely origin of the HIV-1 group M pandemic: 1920s Kinshasa³⁴. Group M virus is responsible for the overwhelming majority of infections worldwide, and within group M, subtype C virus is most prevalent globally³⁵.

However, it was the emergence of subtype B virus in the United States of America that first alerted medical professionals to the global AIDS crisis. A recent high-profile phylogeographic analysis of serum virus has revealed that the early US epidemic probably emerged from an existing epidemic in the Caribbean, which was introduced into New York City in around 1970³⁶.

It has also been proposed that, since the introduction of the virus into the human population, HIV may be becoming less virulent with time. Indeed, there is some evidence to suggest that the extensive global spread of subtype C may be related to relatively lower virulence, despite comparable transmission efficiency³⁷. The rapid rate of evolution has been suggested to contribute to decreased virulence over time by allowing HIV to adapt to protective HLA types, reducing the replicative capacity of the virus³⁸. However, the interpretation of this study has been contested³⁹, and a meta-analysis of the existing literature has previously suggested the converse may be true: that the virulence of HIV is actually increasing⁴⁰. Further investigation is needed to clarify these apparent contradictions, which arguably have important translational implications. One possible explanation for the discrepancies between studies is that virulence may differ geographically as a result of considerable differences in the distribution of HLA class I types and HIV-1 subtypes globally.

The evolutionary virologist's toolkit

The number of resources available to evolutionary virologists has expanded dramatically over recent years. The latest technological advances in computing power have permitted high-level analyses of datasets to be performed, and innovative next-generation sequencing (NGS) platforms have increased—almost exponentially—the amount of data that can be collected from a sample.

Many sequencing studies continue to be performed using the conventional Sanger approach, and these investigations yield interesting and important results. The application of Bayesian Markov Chain Monte Carlo (MCMC) methods in the field of phylogenetics has revolutionised the way that sequence data are interpreted. This approach has been popularised in large part by the ability to incorporate *a priori* information about the sequences such as sampling dates. Such time-stamped data can be used to predict sequence divergence times owing to the robust molecular clock of HIV, which is itself under early immune selection pressure⁴¹. Bayesian analyses also allow a large number of inferences to be drawn from sequencing data and can, for example, be used to reconstruct population dynamics⁴² and transmission networks⁴³.

Whilst Sanger sequencing remains popular, a number of limitations are associated with traditional methods. For example, HIV sequence clustering is known to be heavily confounded by low sampling density⁴⁴, short sequence lengths, and suboptimal inclusion of informative sites⁴⁵. NGS has therefore been embraced in recent years, as it facilitates rapid, high-throughput, and cost-effective analysis of viral quasispecies. Full-length genomes can be amplified, sequenced, and assembled without bias⁴⁶, and the datasets generated can be of sufficient depth to allow reliable detection of ultra-rare mutations at frequencies as low as 0.2%⁴⁷.

Much can be learned from analysing deep sequencing data: indeed, NGS of longitudinally collected whole viral genomes from untreated patients has shown that reproducible patterns in sequence diversity between patients mirror those seen on a global scale, indicating that the fitness costs controlling diversity are universally conserved⁴⁸. NGS may also play an increasingly central role in clinical settings by facilitating the detection and sequencing of low-abundance virus to monitor patients for the emergence of drug-resistant variants⁴⁹.

NGS offers up a number of exciting opportunities for evolutionary virologists, but it is not without its own limitations. Much like Sanger sequencing, there are many possible sources of error⁵⁰ and, even if these are effectively overcome, the sheer size of datasets and the short fragment sizes generated may pose logistical challenges in their analysis. Progress is being made in developing novel frameworks to facilitate phylogenetic reconstruction of NGS data⁵¹, but such approaches are not yet the *status quo*.

Concluding remarks

Over recent years, a clearer picture is being formed as to how, where, and why HIV is evolving. Understanding how the virus evolves within an individual patient is central to the development of appropriate drugs and vaccines, as rapid evolution constitutes a key evasion mechanism against the immune response. Studies of viral evolution between hosts have demonstrated somewhat slower rates of evolution but have also indicated that HIV may be changing in virulence over time.

Advanced analyses and disruptive technologies have been pivotal to recent breakthroughs, and the innovative approaches being developed today will surely shape our understanding of evolutionary virology tomorrow. Particularly promising is the application of NGS to study viral evolution, as the depth and coverage of sequences

generated exceed what is achievable through conventional means. In addition to being of academic interest, this technology may have important clinical implications in the future by facilitating the early detection of low-frequency drug resistance mutations and subsequently allowing alteration and optimisation of treatment plans.

To summarise, owing to a growing body of high-quality research, made possible by cutting-edge technology, HIV evolution is no longer the great enigma it once was. There are still outstanding questions to be answered, but, as more and more of these are answered, the prospect of an effective vaccine or cure becomes increasingly tangible.

Competing interests

The authors confirm that they have no competing interests.

Grant information

Sarah Rowland-Jones is supported by grants from the Rosetrees Foundation (A1138), Globvac (Norwegian Research Council), and the Centre for AIDS Research, Kumamoto University. Sophie M. Andrews is supported by the Rosetrees Trust (A1138).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References




- Cuevas JM, Geller R, Garijo R, *et al.*: **Extremely High Mutation Rate of HIV-1 In Vivo.** *PLoS Biol.* 2015; **13**(9): e1002251.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Lemey P, Rambaut A, Pybus OG: **HIV evolutionary dynamics within and among hosts.** *AIDS Rev.* 2006; **8**(3): 125–40.
[PubMed Abstract](#)
- Alizon S, Fraser C: **Within-host and between-host evolutionary rates across the HIV-1 genome.** *Retrovirology.* 2013; **10**: 49.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Coffin J, Swanstrom R: **HIV pathogenesis: dynamics and genetics of viral populations and infected cells.** *Cold Spring Harb Perspect Med.* 2013; **3**(1): a012526.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Vuilleumier S, Bonhoeffer S: **Contribution of recombination to the evolutionary history of HIV.** *Curr Opin HIV AIDS.* 2015; **10**(2): 84–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Malim MH, Bieniasz PD: **HIV Restriction Factors and Mechanisms of Evasion.** *Cold Spring Harb Perspect Med.* 2012; **2**(5): a006940.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Berkhout B, de Ronde A: **APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations.** *AIDS.* 2004; **18**(13): 1861–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ebrahimi D, Anwar F, Davenport MP: **APOBEC3 has not left an evolutionary footprint on the HIV-1 genome.** *J Virol.* 2011; **85**(17): 9139–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Armitage AE, Deforche K, Chang CH, *et al.*: **APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete “all or nothing” phenomenon.** *PLoS Genet.* 2012; **8**(3): e1002550.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kim EY, Lorenzo-Redondo R, Little SJ, *et al.*: **Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection.** *PLoS Pathog.* 2014; **10**(7): e1004281.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Delviks-Frankenberry KA, Nikolaitchik OA, Burdick RC, *et al.*: **Minimal Contribution of APOBEC3-Induced G-to-A Hypermutation to HIV-1 Recombination and Genetic Variation.** *PLoS Pathog.* 2016; **12**(5): e1005646.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Garcia-Knight MA, Slyker J, Payne BL, *et al.*: **Viral Evolution and Cytotoxic T Cell Restricted Selection in Acute Infant HIV-1 Infection.** *Sci Rep.* 2016; **6**: 29536.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kawashima Y, Pfafferott K, Frater J, *et al.*: **Adaptation of HIV-1 to human leukocyte antigen class I.** *Nature.* 2009; **458**(7238): 641–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Carlson JM, Le AQ, Shahid A, *et al.*: **HIV-1 adaptation to HLA: a window into virus-host immune interactions.** *Trends Microbiol.* 2015; **23**(4): 212–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Dong T, Zhang Y, Xu KY, *et al.*: **Extensive HLA-driven viral diversity following a narrow-source HIV-1 outbreak in rural China.** *Blood.* 2011; **118**(1): 98–106.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Martinez-Picado J, Deeks SG: **Persistent HIV-1 replication during antiretroviral therapy.** *Curr Opin HIV AIDS.* 2016; **11**(4): 417–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Brodin J, Zanini F, Thebo L, *et al.*: **Establishment and stability of the latent HIV-1 DNA reservoir.** *eLife.* 2016; **5**: pii: e18889.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Derdeyn CA, Decker JM, Bibollet-Ruche F, *et al.*: **Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.** *Science.* 2004; **303**(5666): 2019–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Abrahams MR, Anderson JA, Giorgi EE, *et al.*: **Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants.** *J Virol.* 2009; **83**(8): 3556–67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Keele BF, Giorgi EE, Salazar-Gonzalez JF, *et al.*: **Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.** *Proc Natl Acad Sci U S A.* 2008; **105**(21): 7552–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Shankarappa R, Gupta P, Learn GH Jr, *et al.*: **Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles.** *Virology.* 1998; **241**(2): 251–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Markham RB, Wang WC, Weisstein AE, *et al.*: **Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline.** *Proc Natl Acad Sci U S A.* 1998; **95**(21): 12568–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bielejec F, Lemey P, Baele G, *et al.*: **Inferring heterogeneous evolutionary processes through time: from sequence substitution to phylogeography.** *Syst Biol.* 2014; **63**(4): 493–504.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Lemey P, Kosakovsky Pond SL, Drummond AJ, *et al.*: **Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics.** *PLoS Comput Biol.* 2007; **3**(2): e29.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Templeton AR, Kramer MG, Jarvis J, *et al.*: **Multiple-infection and recombination in HIV-1 within a longitudinal cohort of women.** *Retrovirology.* 2009; **6**: 54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lythgoe KA, Fraser C: **New insights into the evolutionary rate of HIV-1 at the within-host and epidemiological levels.** *Proc Biol Sci.* 2012; **279**(1741): 3367–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Vrancken B, Rambaut A, Suchard MA, *et al.*: **The genealogical population dynamics of HIV-1 in a large transmission chain: bridging within and among host evolutionary rates.** *PLoS Comput Biol.* 2014; **10**(4): e1003505.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Immonen TT, Leitner T: **Reduced evolutionary rates in HIV-1 reveal extensive latency periods among replicating lineages.** *Retrovirology.* 2014; **11**: 81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Carlson JM, Schaefer M, Monaco DC, *et al.*: **HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck.** *Science.* 2014; **345**(6193): 1254031.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**

30. **F** Tully DC, Ogilvie CB, Batorsky RE, *et al.*: **Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus.** *PLoS Pathog.* 2016; **12**(5): e1005619.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
31. **F** Carlson JM, Du VY, Pfeifer N, *et al.*: **Impact of pre-adapted HIV transmission.** *Nat Med.* 2016; **22**(6): 606–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
32. Salemi M, Strimmer K, Hall WW, *et al.*: **Dating the common ancestor of SIVcpz and HIV-1 group M and the origin of HIV-1 subtypes using a new method to uncover clock-like molecular evolution.** *FASEB J.* 2001; **15**(2): 276–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Lemey P, Pybus OG, Wang B, *et al.*: **Tracing the origin and history of the HIV-2 epidemic.** *Proc Natl Acad Sci U S A.* 2003; **100**(11): 6588–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. **F** Faria NR, Rambaut A, Suchard MA, *et al.*: **HIV epidemiology. The early spread and epidemic ignition of HIV-1 in human populations.** *Science.* 2014; **346**(6205): 56–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
35. Hemelaar J, Gouws E, Ghys PD, *et al.*: **Global trends in molecular epidemiology of HIV-1 during 2000–2007.** *AIDS.* 2011; **25**(5): 679–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. **F** Worobey M, Watts TD, McKay RA, *et al.*: **1970s and ‘Patient 0’ HIV-1 genomes illuminate early HIV/AIDS history in North America.** *Nature.* 2016; **539**(7627): 98–101.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
37. Ariën KK, Vanham G, Arts EJ: **Is HIV-1 evolving to a less virulent form in humans?** *Nat Rev Microbiol.* 2007; **5**(2): 141–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. **F** Payne R, Muenchhoff M, Mann J, *et al.*: **Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence.** *Proc Natl Acad Sci U S A.* 2014; **111**(50): E5393–400.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
39. Jefferys RJ: **Evidence for HIV weakening over time.** *Proc Natl Acad Sci U S A.* 2015; **112**(17): E2118.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Herbeck JT, Müller V, Maust BS, *et al.*: **Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission.** *AIDS.* 2012; **26**(2): 193–205.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. **F** Park SY, Love TM, Perelson AS, *et al.*: **Molecular clock of HIV-1 envelope genes under early immune selection.** *Retrovirology.* 2016; **13**(1): 38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
42. Drummond AJ, Rambaut A, Shapiro B, *et al.*: **Bayesian coalescent inference of past population dynamics from molecular sequences.** *Mol Biol Evol.* 2005; **22**(5): 1185–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. **F** Didelot X, Gardy J, Colijn C: **Bayesian inference of infectious disease transmission from whole-genome sequence data.** *Mol Biol Evol.* 2014; **31**(7): 1869–79.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
44. **F** Novitsky V, Moyo S, Lei Q, *et al.*: **Impact of sampling density on the extent of HIV clustering.** *AIDS Res Hum Retroviruses.* 2014; **30**(12): 1226–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
45. **F** Novitsky V, Moyo S, Lei Q, *et al.*: **Importance of Viral Sequence Length and Number of Variable and Informative Sites in Analysis of HIV Clustering.** *AIDS Res Hum Retroviruses.* 2015; **31**(5): 531–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
46. Gall A, Ferns B, Morris C, *et al.*: **Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes.** *J Clin Microbiol.* 2012; **50**(12): 3838–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. **F** Zanini F, Brodin J, Albert J, *et al.*: **Error rates, PCR recombination, and sampling depth in HIV-1 whole genome deep sequencing.** *Virus Res.* 2016; pii: S0168-1702(16)30422-1.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
48. **F** Zanini F, Brodin J, Thebo L, *et al.*: **Population genomics of inpatient HIV-1 evolution.** *eLife.* 2015; **4**: pii: e11282.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
49. **F** Gibson RM, Schmotzer CL, Quiñones-Mateu ME: **Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use?** *Curr Infect Dis Rep.* 2014; **16**(4): 401.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
50. McElroy K, Thomas T, Luciani F: **Deep sequencing of evolving pathogen populations: applications, errors, and bioinformatic solutions.** *Microb Inform Exp.* 2014; **4**(1): 1.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. **F** Dialdestoro K, Sibbesen JA, Maretty L, *et al.*: **Coalescent Inference Using Serially Sampled, High-Throughput Sequencing Data from Intrahost HIV Infection.** *Genetics.* 2016; **202**(4): 1449–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Referee Status:



Editorial Note on the Review Process

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

The referees who approved this article are:

Version 1

- 1 **Ben Berkhout**, Laboratory of Experimental Virology (LEV), Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center (AMC), University of Amsterdam (UvA), Amsterdam, Netherlands
Competing Interests: No competing interests were disclosed.
- 1 **Philippe Lemey**, Department of Microbiology and Immunology, Rega Institute, KU Leuven, Leuven, Belgium
Competing Interests: No competing interests were disclosed.